VEREIT, Inc. (VER) At $6.88 Forms Bottom; Numeric Investors Has Increased Meridian Bioscience (VIVO) Position By $574,600

Meridian Bioscience, Inc. (NASDAQ:VIVO) Logo

Numeric Investors Llc increased Meridian Bioscience Inc (VIVO) stake by 38.18% reported in 2017Q4 SEC filing. Numeric Investors Llc acquired 44,200 shares as Meridian Bioscience Inc (VIVO)’s stock rose 1.05%. The Numeric Investors Llc holds 159,963 shares with $2.24 million value, up from 115,763 last quarter. Meridian Bioscience Inc now has $607.12 million valuation. The stock decreased 0.35% or $0.05 during the last trading session, reaching $14.35. About 122,101 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 7.87% since April 12, 2017 and is uptrending. It has underperformed by 3.68% the S&P500.

VEREIT, Inc. (VER) formed multiple bottom with $6.47 target or 6.00% below today’s $6.88 share price. VEREIT, Inc. (VER) has $6.84 billion valuation. The stock increased 0.15% or $0.01 during the last trading session, reaching $6.88. About 5.50 million shares traded. VEREIT, Inc. (NYSE:VER) has declined 19.24% since April 12, 2017 and is downtrending. It has underperformed by 30.79% the S&P500.

Numeric Investors Llc decreased Exterran Corp stake by 119,761 shares to 479,668 valued at $15.08M in 2017Q4. It also reduced Northeast Bancorp (NASDAQ:NBN) stake by 17,183 shares and now owns 57,462 shares. Fonar Corp (NASDAQ:FONR) was reduced too.

Since February 7, 2018, it had 2 insider buys, and 0 selling transactions for $28,784 activity. The insider McIlwraith John bought $14,034. Rice John McCune Jr. bought $14,750 worth of stock or 1,000 shares.

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 13 analyst reports since July 28, 2015 according to SRatingsIntel. The company was upgraded on Monday, March 28 by Hilliard Lyons. The rating was maintained by Robert W. Baird on Thursday, January 25 with “Hold”. Piper Jaffray maintained it with “Sell” rating and $900 target in Thursday, July 27 report. Piper Jaffray maintained the shares of VIVO in report on Thursday, January 25 with “Sell” rating. Canaccord Genuity maintained the stock with “Hold” rating in Thursday, September 10 report. Robert W. Baird maintained it with “Hold” rating and $15.0 target in Thursday, October 19 report. Hilliard Lyons downgraded Meridian Bioscience, Inc. (NASDAQ:VIVO) on Monday, March 21 to “Neutral” rating. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Hold” rating given on Thursday, January 25 by Canaccord Genuity. The rating was maintained by Piper Jaffray on Thursday, October 19 with “Sell”. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) earned “Sell” rating by Piper Jaffray on Thursday, September 21.

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 0.17, from 1.37 in 2017Q3. It dived, as 21 investors sold VIVO shares while 44 reduced holdings. 31 funds opened positions while 47 raised stakes. 36.52 million shares or 0.72% more from 36.26 million shares in 2017Q3 were reported. Prudential Fincl owns 376,224 shares. Greylin Mangement stated it has 0.25% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Comml Bank Of Montreal Can reported 1,737 shares. Teacher Retirement Systems Of Texas reported 14,456 shares. Meeder Asset Management Incorporated reported 925 shares. Moreover, Millennium Management Ltd Liability Co has 0.02% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Koch has 14,412 shares for 0.03% of their portfolio. Aperio Group Llc invested in 0% or 44,650 shares. Sei Invests invested in 0% or 160 shares. Brown Limited Liability has invested 0.79% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Hotchkis And Wiley Cap Ltd reported 27,205 shares. Barclays Public Ltd Co owns 22,488 shares. Legal & General Group Public Ltd Com holds 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO) or 87,493 shares. 200 are owned by Prentiss Smith And. Gabelli Funds Limited Liability stated it has 0.02% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO).

Meridian Bioscience, Inc. (NASDAQ:VIVO) Institutional Positions Chart